-
1 Comment
Master Pharm S.A. is currently in a long term downtrend where the price is trading 5.1% below its 200 day moving average.
Master Pharm S.A.'s total revenue sank by 22.0% to $16M since the same quarter in the previous year.
Its net income has dropped by 20.3% to $3M since the same quarter in the previous year.
Finally, its free cash flow grew by 396.3% to $11M since the same quarter in the previous year.
Based on the above factors, Master Pharm S.A. gets an overall score of 1/5.
| ISIN | PLMSTPH00016 |
|---|---|
| CurrencyCode | PLN |
| Industry | Personal Products |
| Sector | Consumer Staples |
| Exchange | WAR |
| Market Cap | 109M |
|---|---|
| Beta | 0.57 |
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | 31.84 |
Master Pharm SA designs and manufactures diet supplements, special nutritional food, dietary products, cosmetics, medical devices, and other consumables in Poland. It also offers contract manufacturing services and product document preparation services. In addition, the company imports and exports supplements and medical devices; and engages in designing, manufacturing, subcontracting, and distributing, as well as conformity assessment for CE mark, and registration of medical devices. Master Pharm SA was formerly known as Master Pharm Poland Ltd. The company was founded in 2002 and is based in Lodz, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MPH.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
